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Prevention of relapse of Plasmodium vivax infection is a key
treatment goal in malaria. Use of P. vivax genotyping in a mul-
ticenter, double-blind, randomized, placebo-controlled phase
2b study in Peru, India, Thailand, and Brazil allowed determi-
nation of genetically heterologous or homologous P. vivax in-
fection recurrence following receipt of chloroquine plus one
of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloro-
quine plus primaquine, compared with receipt of chloroquine
alone. The antihypnozoite efﬁcacy of tafenoquine was evident
as a reduction in homologous recurrences of P. vivax infection
as drug doses were increased. No clear dose-response pattern
was evident for heterologous recurrences of P. vivax infection.
Rates of homologous recurrence of P. vivax infection appear to
be clinically useful for comparing drug efﬁcacy for the preven-
tion of P. vivax infection relapse.
Clinical Trials Registration. NCT01376167.
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One third of the world’s population is at risk for Plasmodium
vivax malaria [1]. Periodic reactivation of a dormant liver
stage, the hypnozoite, causes repeated clinical relapses of a sin-
gle P. vivax infection (hereafter referred to as “P. vivax relapse”).
Prevention of P. vivax relapses is a key treatment goal in malaria
because of their signiﬁcant morbidity and economic burden [2].
Also, as the hypnozoite reservoir maintains the potential for
further transmission, relapse prevention is essential for effective
malaria control and eradication.
Tafenoquine is an 8-aminoquinoline in development as a sin-
gle-dose treatment for the prevention of P. vivax relapse. Eval-
uating drugs to prevent P. vivax relapse is challenging because
recurrent P. vivax infection (hereafter, “P. vivax recurrence”)
cannot be easily resolved into recrudescence (ie, failure to
treat the initial infection), reinfection (ie, new infection), or re-
lapse (ie, hypnozoite reactivation). Recently, evaluation tech-
niques for P. vivax genotype markers have been developed,
based on capillary electrophoresis [3, 4] and amplicon deep
sequencing [5]. Although distinguishing between the causes of
parasite recurrence remains problematic, genotyping improves
the evaluation of drug efﬁcacy, compared with microscopy
alone [3–5].
This study reports P. vivax genotyping data from a multicen-
ter, double-blind, randomized, placebo-controlled phase 2b ta-
fenoquine dose-selection study (DETECTIVE; clinical trials
registration NCT01376167), conducted across 7 sites in Peru,
India, Thailand, and Brazil [6]. Treatment with the antihypno-
zoite drugs tafenoquine (50, 100, 300, and 600 mg) and prima-
quine, in combination with chloroquine, were compared to
treatment with chloroquine alone, to determine their effect on
the frequency of genetically heterologous or homologous P.
vivax recurrences.
METHODS
This clinical trial conformed to good clinical practice, the Dec-
laration of Helsinki (2000), and all applicable regulatory re-
quirements. Protocol approval was obtained from each study
site’s ethics committee or institutional review board. Written
informed consent was obtained from subjects or from parents
or guardians of subjects combined with the subject’s assent.
Full study methods have been reported previously [6].
Eligible patients were of either sex, aged ≥16 years, and had
microscopically conﬁrmed P. vivax monoinfection (parasite
density, >100 to <100 000 parasites/µL blood). Major exclusion
criteria were recent antimalarial treatment, severe malaria, con-
current illness, pregnancy/lactation, and glucose-6-phosphate
dehydrogenase enzyme activity of <70% of the derived site pop-
ulation reference value, owing to the hemolysis risk with 8-
aminoquinolines.
All enrolled patients received once-daily oral chloroquine
on day 1 (600 mg), day 2 (600 mg), and day 3 (300 mg). Pa-
tients were randomly assigned to one of 6 treatment groups:
single-dose oral tafenoquine on day 1 or 2 at doses of 50 mg
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(n = 55), 100 mg (n = 57), 300 mg (n = 57), or 600 mg
(n = 56); oral primaquine 15 mg for 14 days (n = 50); or chlo-
roquine alone (n = 54).
Patients were followed up for 180 days. Giemsa-stained thick
blood smears for parasite assessments were performed at
screening; after treatment on day 1 and days 2 and 3 twice
daily every 6–12 hours until parasite clearance; and on days 8,
15, 22, 29, 60, 90, 120, and 180 or when the patient presented
with malaria symptoms.
In the case of P. vivax recurrence, parasite genomic DNAwas
ampliﬁed from blood specimens collected using the dried blood
spot technique on FTAClassic Cards (Whatman, Germany) ac-
cording to the manufacturer’s protocol (BD08). Genotyping
was performed using published methods [3]. Primary multiplex
polymerase chain reaction (PCR) used published primer se-
quences for 3 discriminatory markers: merozoite surface pro-
tein 1 (msp1F3) and microsatellites MS16 and Pv3.27 [3].
Fifty microliters of primary PCR master mix contained 1× Phu-
sion HF Buffer (New England Biolabs), 1.4 mM dNTPs (Invi-
trogen, Germany), 0.25 µM of each primer (Euroﬁn MWG
Operon, Germany), 1 unit of Phusion High-Fidelity Polymerase
(New England Biolabs), and 1 processed punch (3 mm) from
FTA cards. From the primary multiplex PCR, 0.5 µL of PCR
product was used as a template for nested PCR ampliﬁcation
of msp1F3, MS16, and Pv3.27, using previously published prim-
ers, reaction mix, and thermocycling conditions [3]. PCR prod-
ucts were checked for quality and to estimate the product
amount, using agarose-gel electrophoresis. Failed samples not
yielding PCR products were repeated 3 times. Capillary electro-
phoresis was conducted to determine amplicon sizes [3]. Samples
were analyzed by ABI3130xl, using GS500LIZ as size standard
(Applied Biosystems), and data were analyzed using GeneMap-
per, version 3.7 (Applied Biosystems). Alleles were grouped by
size into 3–base pair bins for coding regions and by repeat length
for microsatellites (3 base pairs for MS16 and 4 base pairs for
Pv3.27). If recurrent infections contained identical alleles for all
3 markers versus the enrollment sample, circumsporozoite pro-
tein (Pvcsp) and apical membrane antigen 1 (Pvama1) loci were
sequenced [7, 8]. Quality control was performed on 20 sample
pairs at the Institute of Tropical Medicine, Antwerp.
Recurrent infections that differed by at least 1 marker from
pretreatment infections were deﬁned as heterologous; all others
were considered homologous. A post hoc Kaplan–Meier analy-
sis (log-rank test) estimated the risk of homologous or heterol-
ogous recurrence for chloroquine, primaquine, low-dose
tafenoquine (50 or 100 mg), and high-dose tafenoquine (300
or 600 mg), with censoring at the time of the event for recurrent
infections not determined as homologous or heterologous, in-
fections in patients who were lost to follow-up, or patients with
no recurrence.
Virtual heterozygosity was calculated using the equation
½n=ðn 1Þ  ½1 S pi2, where n is the number of samples
analyzed and pi is the frequency of the allele i [4]. Mean multi-
plicity of infection (MOI) was estimated for all markers inde-
pendently by dividing the total number of P. vivax clones
detected by the number of samples that were PCR positive for
the parasite.
RESULTS
Of 329 patients recruited to the study and treated, 100 (30.4%)
presented with P. vivax recurrence. Five patients had missing
samples for PCR; thus, 95 of 329 patients (28.9%) had recur-
rences classiﬁed as heterologous or homologous (Figure 1A).
In Peru, 60 of 136 patients had recurrences (30 heterologous
and 30 homologous); in Thailand, 18 of 99 (6 and 12, respec-
tively); in Brazil, 16 of 37 (2 and 14, respectively); and in India, 1
of 57 (0 and 1, respectively). In the Kaplan–Meier analysis, 25
patients were censored at their last visit, owing to missing efﬁ-
cacy outcomes for day 180.
Heterologous recurrences could not be used to distinguish
between tafenoquine doses (Figure 1B). Kaplan–Meier esti-
mates indicated that there was no statistically signiﬁcant differ-
ence in heterologous recurrence rate between high-dose and
low-dose tafenoquine (6.7% and 15.2%, respectively; treatment
difference, −8.5% [95% conﬁdence interval {CI}, −17.9% to
1.0%]; P = .069). Only high-dose tafenoquine produced a statis-
tically signiﬁcant decrease in the heterologous recurrence rate,
compared with chloroquine (treatment difference, −27.5%
[95% CI, −47.4% to −7.6%]; P < .001), although heterologous
recurrences tended to decrease with the 8-aminoquinolines.
Heterologous recurrences in the chloroquine group mostly oc-
curred between days 35 and 50 and were relatively delayed with
tafenoquine.
Both tafenoquine and primaquine have activity against
blood-stage infection, and the long half-life of tafenoquine
may have reduced heterologous recurrences by decreasing the
parasite reinfection rate. However, reinfection is thought to be
infrequent in areas of low endemicity, as in this study, and there
were no treatment failures in the chloroquine group before day
28. All subjects were provided with insecticide-treated bed nets,
although their use was not audited. Thus, prevention of heter-
ologous recurrence could be explained as a combination of
reinfection prophylaxis and the antihypnozoite effect of high-
dose tafenoquine in this setting.
In contrast to the heterologous recurrences, homologous re-
currences showed a dose-response for tafenoquine (Figure 1C).
Kaplan–Meier analysis indicated that the rate of homologous
recurrence was just 2.9% with high-dose tafenoquine, compared
with 31.2% with low-dose tafenoquine (treatment difference,
−28.3% [95% CI, −37.9% to −18.7%]; P < .001). Homologous
recurrences occurred in 39.4% of patients in the chloroquine
group and were signiﬁcantly reduced with high-dose tafeno-
quine (treatment difference, −36.5% [95% CI, −51.8% to
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−21.2%]; P < .001) and primaquine (treatment difference,
−30.5% [95% CI, −47.6% to −13.3%]; P = .001). The effect of
low-dose tafenoquine was similar to that of chloroquine alone
(treatment difference, −8.2% [95% CI, −25.7% to 9.3%];
P = .394).
The observed dose-response for tafenoquine for prevention
of homologous recurrence would be expected if an antihypno-
zoite effect of these drug regimens could be detected. This
strongly suggests that, in areas of low endemicity, homologous
recurrences mainly represent relapses.
There were 3 homologous recurrences with high-dose tafeno-
quine (days 85 and 127 in Brazil and day 105 in Thailand) and
5 in the primaquine group (days 42–189 in Peru). These homolo-
gous recurrences could be attributed to a drug failure against hyp-
nozoites. There is some clinical evidence for primaquine that
associates 2D6 drug metabolism to antihypnozoite drug failure
Figure 1. Plasmodium vivax infection recurrence (hereafter, “P. vivax recurrence”). A, Frequency of genetically heterologous and homologous P. vivax recurrence following
treatment with chloroquine (CQ), with or without one of 4 doses of tafenoquine (TQ), or with CQ and primaquine (PQ). B, Kaplan–Meier analysis of heterologous P. vivax
recurrence following treatment with CQ, with or without high-dose (300 or 600 mg) or low-dose (50 or 100 mg) TQ, or with CQ and PQ. C, Kaplan–Meier analysis of homologous
P. vivax recurrence following treatment with CQ, with or without high-dose (300 or 600 mg) or low-dose (50 or 100 mg) TQ, or with CQ and PQ. Abbreviations: CQ, chloroquine;
PQ, primaquine; TQ, tafenoquine.
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[9]. However, recent analysis of clinical data and prospective pre-
clinical data indicate that this may not be the case for tafenoquine
(St. Jean, unpublished data). Alternatively, if parasite genetic diver-
sity was low, failures could represent homologous reinfection.
To understand the likelihood of homologous recurrences
being caused by relapse versus reinfection, parasite genetic di-
versity was examined. Heterogeneity indices for the microsatel-
lite markers were variable between countries (Figure 2) and
Figure 2. Plasmodium vivax genotype diversity. Pie charts represent allelic frequencies of different-sized fragments for each of 3 potential genetic markers among P. vivax–
positive samples at study sites in Peru (n = 199), Brazil (n = 53), India (n = 38), and Thailand (n = 46), indicating that heterogeneity was generally low. Colored sections denote the
frequencies of identical alleles in each marker in different sites. White sections denote the frequencies of identical alleles that occurred only at the specified site. The lower
chart represents the discernible haplotypes for the Peru site. All sites had only unique haplotypes. Abbreviation: He, virtual heterozygosity index.
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generally consistent with previous reports [10–12]. Genetic di-
versity was mostly low (heterozygosity, 0.59–0.96), with 4–11
different circulating strains. Thus, it is possible that a propor-
tion of homologous recurrences could be caused by reinfection.
Alternatively, for a minority of variants, greater sensitivity of ge-
netic testing may be required to distinguish heterology.
As another indicator of low endemicity in the study areas, a
low mean MOI (±SD) was observed for Brazil (1.06 ± 0.246)
and Peru (1.11 ± 0.318). In areas of high endemicity, much
higher MOI values have been observed (eg, 2.7 in Papua New
Guinea) [4]. The mean MOI estimates (±SD) for Thailand
(1.77 ± 1.07) and India (1.50 ± 0.704) were intermediate and
consistent with previous reports [11, 13].
Notably, in only 4 of 95 paired samples did subsequent se-
quencing of ama1 or csp loci result in a difference between
the pretreatment sample and recurrent sample in cases where
msp1F3, MS16, and Pv3.27 were identical.
DISCUSSION
In this placebo-controlled trial, the effect of antihypnozoite
drug pressure with primaquine or 4 different doses of tafeno-
quine on the genotypes of P. vivax recurrences was deter-
mined. This novel study indicates that it is feasible, within a
clinical trial, to further analyze antihypnozoite efﬁcacy by
P. vivax genotyping with a precision that has relevance for
regulatory assessment. Although data interpretation is not
straightforward, the antihypnozoite drug efﬁcacy of tafeno-
quine was evident as a dose-dependent reduction in homolo-
gous recurrences. No clear dose-response pattern was evident
for heterologous recurrence. Thus, we conclude that the reduc-
tion in homologous recurrences with high-dose tafenoquine is
a consequence of its antihypnozoite effect, resulting in almost
complete suppression of P. vivax relapse. At a population level,
therefore, homologous recurrence rates appear to be a useful
estimate of antihypnozoite drug efﬁcacy in P. vivax relapse
prevention.
A limitation of this analysis is that only pretreatment samples
from patients with recurrences were genotyped. Thus, the true
P. vivax population diversity was likely underestimated. Geno-
typing of all baseline samples would more accurately reﬂect the
parasite genetic diversity in the population. Also, this study was
conducted in regions of low P. vivax endemicity; the MOI was
low, and polyclonal infections were uncommon. Consequently,
our ﬁndings cannot be extrapolated to areas of high endemicity,
where individuals may carry hypnozoites from several parasite
strains, any of which could cause a relapse. Thus, relapses would
be more likely to be heterologous to the initial infection than in
the current study. Importantly, hypnozoites are an important
source of P. vivax infection even in areas of high endemicity.
For example, in Papua New Guinea, treating children with arte-
sunate-primaquine reduced their P. vivax infection risk by 49%
at 3 months after treatment, compared with artesunate alone
[14]. In comparative trials, by determining the proportion of
heterologous versus homologous recurrences, genotyping can
distinguish between recrudescence and reinfection, although
in areas of low parasite genetic diversity there may be some
overlap. However, genotyping cannot distinguish between re-
crudescence and relapse should samples be homologous. Recru-
descence is caused by the failure of chloroquine and will usually
occur within 15 to 28 days of treatment. There was only 1 failure
before day 21 in this study, and this was a heterologous recur-
rence, suggesting that all failures were caused by either reinfec-
tion or relapse.
Tafenoquine is currently being evaluated in phase 3 studies.
At the 300-mg clinical dose, there was a 9-fold reduction in ho-
mologous recurrence, compared with chloroquine, representing
a clinically important impact on P. vivax relapse prevention;
heterologous recurrences were also reduced 3-fold. Overall,
the profound clinical impact of tafenoquine at preventing
P. vivax recurrence has potentially important health and eco-
nomic beneﬁts.
In conclusion, analysis of the frequency of homologous and
heterologous recurrences allowed estimation of tafenoquine’s
antihypnozoite efﬁcacy against P. vivax. This study supports
high-resolution P. vivax genotyping in drug trials aiming to
eliminate P. vivax hypnozoites, although conﬁrmatory studies
are required.
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